N.J. biotech seeks to raise $57.5M by going public

09/19/2013 | American City Business Journals · Xconomy

Aerie Pharmaceuticals, a Bedminster, N.J.-based developer of eye disease treatments, could bring in as much as $57.5 million in an initial public offering. The company plans to use the money to create a sales force and advance its experimental glaucoma drug AR-13324 through a Phase III trial and the drug PG324 through a midstage trial.

View Full Article in:

American City Business Journals · Xconomy

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA
Diagnostic Technician
Roche
Marlborough, MA
Test Technician
Roche
Marlborough, MA
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
Ridgefield, CT